Upto 60% Off on UPSC Online Courses

Avail Now

A Drug Safety Alert Against Use of Meftal

Context: The Indian Pharmacopoeia Commission (IPC) issued a drug safety alert regarding the common painkiller, Meftal.

IPC issues drug safety alert for Meftal

  • This was based on a preliminary analysis conducted on adverse drug reactions by the Pharmacovigilance Programme of India (PvPI).
  • The Commission also advises people to take the drug only after consulting a doctor.
  • Healthcare professionals and patients are advised to be vigilant for signs of DRESS syndrome and other adverse drug reactions.
The Indian Pharmacopoeia Commission (IPC)

  • It is an Autonomous Body, under administrative control of the Ministry of Health and Family Welfare.

Chairperson: The Secretary, Ministry of Health and Family Welfare.

Mandate: 

  • Revision and publication of the Indian Pharmacopoeia (the official book of standards for drug ).
  • National formulary of India on a regular basis besides providing IP Reference Substances and training to the stakeholders on Pharmacopoeial issues.

Pharmacovigilance Programme of India:

  • It  is Government of India’s flagship drug safety monitoring programme, which collects, collates and analyses drug-related adverse events (AEs).

About Meftal:

  • Meftal is a commonly used non-steroidal anti-inflammatory drug (NSAID).
  • The primary component of Meftal is Mefenamic acid, a pain-relieving medication employed to mitigate muscle and joint discomfort as well as menstrual pain (menstrual cramps and rheumatoid arthritis). 
  • Drug Action: Reduce the production of prostaglandins, which increases the pain sensation.
  • Use: It is  commonly prescribed for various conditions such as rheumatoid arthritis, osteoarthritis, dysmenorrhoea, mild to moderate pain, inflammation, fever, and dental pain.
  • Risk and Side effects: In addition to DRESS syndrome, other side effects such as abdominal pain, indigestion, dry mouth, blurred vision, increased blood pressure, swelling and gastrointestinal issues like stomach ulcers and bleeding.

DRESS Syndrome: 

  • The Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome is a rare and potentially life-threatening reaction to a medication.
  • Symptoms: Fever, Skin rash, Lymphadenopathy, eosinophilia, and a spectrum of systemic manifestations ranging from mild to severe.

Source: Livemint

 

Print Friendly, PDF & Email

To get PDF version, Please click on "Print PDF" button.

Print Friendly, PDF & Email

 Final Result – CIVIL SERVICES EXAMINATION, 2023.   Udaan-Prelims Wallah ( Static ) booklets 2024 released both in english and hindi : Download from Here!     Download UPSC Mains 2023 Question Papers PDF  Free Initiative links -1) Download Prahaar 3.0 for Mains Current Affairs PDF both in English and Hindi 2) Daily Main Answer Writing  , 3) Daily Current Affairs , Editorial Analysis and quiz ,  4) PDF Downloads  UPSC Prelims 2023 Trend Analysis cut-off and answer key

THE MOST
LEARNING PLATFORM

Learn From India's Best Faculty

      

 Final Result – CIVIL SERVICES EXAMINATION, 2023.   Udaan-Prelims Wallah ( Static ) booklets 2024 released both in english and hindi : Download from Here!     Download UPSC Mains 2023 Question Papers PDF  Free Initiative links -1) Download Prahaar 3.0 for Mains Current Affairs PDF both in English and Hindi 2) Daily Main Answer Writing  , 3) Daily Current Affairs , Editorial Analysis and quiz ,  4) PDF Downloads  UPSC Prelims 2023 Trend Analysis cut-off and answer key

Quick Revise Now !
AVAILABLE FOR DOWNLOAD SOON
UDAAN PRELIMS WALLAH
Comprehensive coverage with a concise format
Integration of PYQ within the booklet
Designed as per recent trends of Prelims questions
हिंदी में भी उपलब्ध
Quick Revise Now !
UDAAN PRELIMS WALLAH
Comprehensive coverage with a concise format
Integration of PYQ within the booklet
Designed as per recent trends of Prelims questions
हिंदी में भी उपलब्ध

<div class="new-fform">







    </div>

    Subscribe our Newsletter
    Sign up now for our exclusive newsletter and be the first to know about our latest Initiatives, Quality Content, and much more.
    *Promise! We won't spam you.
    Yes! I want to Subscribe.